Use of Patient Reported Outcome Measurements Information in Clinical Practice in Spain for the Clinical Management of Psoriasis Patients—Summer Project

ABSTRACT Background Routine collection of patient perspectives about psoriasis and its treatment through patient reported outcome measurements (PROMs), alongside clinician reported outcome measurements (CROMs), may improve clinical outcomes and facilitate shared decision making. Objectives This study aimed to assess the impact of using PROMs on evaluating treatments in patients with moderate to severe psoriasis. Methods The SUMMER Project is a multicenter study examining the characteristics, severity, treatment, healthcare resource use and quality‐of‐life impact of moderate to severe psoriasis patients in Spain. Data extracted from medical records, partly through natural language processing, included demographics, clinical data and CROMs (Psoriasis Area Severity Index‐PASI and body surface area‐BSA). PROMs collected through a platform every 3 months included Dermatology life quality index (DLQI) to assess HRQoL, 10‐point Visual Analogic Scale (VAS) to assess psoriasis global impact, and Treatment Satisfaction Questionnaire for Medication (TSQM‐9). Results Out of 222 patients from 5 hospitals, 147 were analyzed. The mean age was 48.2 years, with 58.5% males. Most (88.9%) were on biologic treatment for psoriasis, while 18.8% were on conventional systemic treatment. At the start, 7.3% had severe psoriasis symptoms (PASI ≥ 5 and/or BSA ≥ 3). The median baseline DLQI was 3.0, with 21.0% scoring ≥ 5. The average VAS score was 2.4, with 12.5% scoring ≥ 7. Mean global TSQM‐9 score was 80.6. During follow‐up, 9.6% changed treatment. At the time of change, 53.8% had mild symptoms (PASI ≤ 3), 30.8% had severe symptoms (PASI ≥ 5), and 68.8% had high DLQI and/or VAS scores. Those who changed treatment showed significant improvement in DQLI and VAS scores. Conclusions Most psoriasis patients maintained stable treatment, with good HRQoL. Few patients reported a significant impact on HRQoL and changed their treatment. PROs can play an important role in shared decision making to change treatment in routine clinical practice, even for patients achieving excellent clinical outcomes.

Authors

Institutions

Publication Details

Journal
JEADV Clinical Practice
Published
2026-04-14
DOI
https://doi.org/10.1002/jvc2.70226
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Use of Patient Reported Outcome Measurements Information in Clinical Practice in Spain for the Clinical Management of Psoriasis Patients—Summer Project

Manuel Cuervas-Mons, Cynthia Novella, Conrad Pujol, Jorge Magdaleno-Tapial et al.
JEADV Clinical Practice
Psoriasis: Treatment and Pathogenesis
article

Use of Patient Reported Outcome Measurements Information in Clinical Practice in Spain for the Clinical Management of Psoriasis Patients—Summer Project

Manuel Cuervas-Mons, Cynthia Novella, Conrad Pujol, Jorge Magdaleno-Tapial, Pablo de la Cueva, Jaime Notario, Raquel Rivera, Josep Riera‐Monroig
article en

Abstract

ABSTRACT Background Routine collection of patient perspectives about psoriasis and its treatment through patient reported outcome measurements (PROMs), alongside clinician reported outcome measurements (CROMs), may improve clinical outcomes and facilitate shared decision making. Objectives This study aimed to assess the impact of using PROMs on evaluating treatments in patients with moderate to severe psoriasis. Methods The SUMMER Project is a multicenter study examining the characteristics, severity, treatment, healthcare resource use and quality‐of‐life impact of moderate to severe psoriasis patients in Spain. Data extracted from medical records, partly through natural language processing, included demographics, clinical data and CROMs (Psoriasis Area Severity Index‐PASI and body surface area‐BSA). PROMs collected through a platform every 3 months included Dermatology life quality index (DLQI) to assess HRQoL, 10‐point Visual Analogic Scale (VAS) to assess psoriasis global impact, and Treatment Satisfaction Questionnaire for Medication (TSQM‐9). Results Out of 222 patients from 5 hospitals, 147 were analyzed. The mean age was 48.2 years, with 58.5% males. Most (88.9%) were on biologic treatment for psoriasis, while 18.8% were on conventional systemic treatment. At the start, 7.3% had severe psoriasis symptoms (PASI ≥ 5 and/or BSA ≥ 3). The median baseline DLQI was 3.0, with 21.0% scoring ≥ 5. The average VAS score was 2.4, with 12.5% scoring ≥ 7. Mean global TSQM‐9 score was 80.6. During follow‐up, 9.6% changed treatment. At the time of change, 53.8% had mild symptoms (PASI ≤ 3), 30.8% had severe symptoms (PASI ≥ 5), and 68.8% had high DLQI and/or VAS scores. Those who changed treatment showed significant improvement in DQLI and VAS scores. Conclusions Most psoriasis patients maintained stable treatment, with good HRQoL. Few patients reported a significant impact on HRQoL and changed their treatment. PROs can play an important role in shared decision making to change treatment in routine clinical practice, even for patients achieving excellent clinical outcomes.

JEADV Clinical Practice
Johnson & Johnson (United States) (US), Bellvitge University Hospital (ES), Hospital Universitari i Politècnic La Fe (ES), Research Institute Hospital 12 de Octubre (ES), Hospital Clínic de Barcelona (ES), Hospital General Universitario De Valencia (ES), Johnson & Johnson (Brazil) (BR), Hospital Universitario Infanta Leonor (ES), Universitat de Barcelona (ES)
Openalex Percentile: Top 24%
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.